by Raynovich Rod | Jul 27, 2012 | BIOgraph, Macro
Vague talk about Monetary Actions in Europe Sparks Broad Three Day Rally It started yesterday with Draghi saying that ECB actions are being proposed that would reduce bond yields in Italy and Spain. Draghi will hold talks with Bundesbank President Jens Weidmann in...
by Raynovich Rod | Jun 28, 2012 | BIOgraph, Biopharmaceuticals, Macro
Update 1 Mid-day Trading -June 29 Bulls Back in Charge on EU Bank Bailout The market has forgotten about Obamacare and reverted to the number one market issue-Euro debt resolution. Here is a healthcare sector update from today’s trading and our take:...
by Raynovich Rod | Jun 22, 2012 | Biopharmaceuticals, Macro, Reading List
BioBuzz Rolls On After a bad day on NASDAQ yesterday with some profit taking in biotech there is a lot of green screen today. The sector is up 1% today and we are near all time highs like the XBI ($86.92). But to many investors, biotechnology is relatively unknown or...
by Raynovich Rod | Jun 21, 2012 | BIOgraph, Biopharmaceuticals, Energy, Macro
Sell-off gets worse with S&P down 2%. Moody’s downgrade of banks expected by end of day. Bear market for commodities? ———– We have been at BIO 2012 in Boston over the past week and will provide interesting trends and data from the...
by Raynovich Rod | Jun 1, 2012 | BIOgraph, Macro
Jobs Number Spooks Traders-Dow Erases Gains for the Year Large cap biotechnology and MO growth stocks are taking a big hit today as hedgies take profits. Many of these stocks are still up YTD but profits are quickly eroding. Stocks to watch in technology, retail and...
by Raynovich Rod | May 30, 2012 | BIOgraph, Macro
Look for biotechnology intermediate top as we approach ASCO next week. Market is now driven by hedgies and big funds.IBB ($123.90) double top with YTD high of $126.90 Mid cap biotech index off 1.7%. DX and tools also very weak. S&P unchanged from one year...
by Raynovich Rod | May 17, 2012 | 2024 Rayno Biopharmaceuticals Portfolio, Macro
Facebook Hype Effect-Sell MO Stocks? Many of the favorite momentum stocks are being hit with profit taking today including large cap biopharmaceutical stocks. With the NASDAQ down 0.8% at 2850, we see a lot of countertrends like gold up $39.70 off recent lows to...
by Raynovich Rod | May 4, 2012 | BIOgraph, Biopharmaceuticals, Macro
The NASDAQ Biotechnology Index IBB ($122.30) is off 1.5% today and more than 2% off its all time high of $126.65. The first clue to the current sell-off was a CNBC Fast Money Contributor to buy the ETF XBI ($79) earlier in the week at its top of $82. Earlier this...
by Raynovich Rod | Apr 23, 2012 | Biopharmaceuticals, Macro
Biotech Outperforming Tech Lately: M&A Hit of the Day Ardea Biosciences The market continues its choppy trend with the QQQ’s off 0.9% to $65 with some Internet high fliers like AMZN and NFLX taking a hit. But biotech recovered from earlier losses with the...
by Raynovich Rod | Mar 14, 2012 | Macro
There Is A Fork In the Road-Do you Take It? The past two days have shown some very dramatic trends in the market. But we will not discuss the parabolics of AAPL $589 stock up 8% in five days which you all know (Will newbies get into AAPL now?). Here are some key...
